Hubungan Antagonis Leukotrien dengan Tingkat Kontrol Asma di Klinik Harum Melati
The level of asthma control is the extent to which the characteristics of asthma can be observed in patients with asthma and have been reduced or disappear with treatment. The Global Initiative for Asthma guidelines recommends leukotriene antagonists as the second-line add-on treatment. Leukotriene antagonists play a role in controlling the recurrence of asthma symptoms, so a well-controlled asthma patient will be achieved. This study conducted to find out the correlations between the use of leukotriene antagonists with the level of asthma control in patients with bronchial asthma at Harum Melati Clinic of Pringsewu in August 2018-August 2019. Methodology: This research using an analytic method with a retrospective approach. The population of this research was all of the medical records of patients with bronchial asthma at Harum Melati Clinic of Pringsewu on the period of August 2018-August 2019, amounting to 449, sampling using the total sampling technique with the total sample of 232 medical records that meet the inclusion criteria and exclusion criteria. Data were analyzed by the spearman test. 133 (57.3%) subjects had well-controlled asthma, 99 (42.7%) subjects having partly- controlled asthma, and there are no asthma patients have uncontrolled asthma (0%). And also got 125 (53.9%) subjects using leukotriene antagonists and 107 (46.1%) subjects did not use leukotriene antagonists. There is a correlation between the use of leukotriene antagonists with the level of asthma control in patients with bronchial asthma at Harum Melati Clinic of Pringsewu in August 2018-August 2019.
Jurnal ARTERI memberikan akses terbuka terhadap siapapun agar informasi dan temuan pada artikel tersebut bermanfaat bagi semua orang. Semua konten artikel dalam jurnal ini dapat diakses dan diunduh secara gratis, tanpa dipungut biaya, sesuai dengan lisensi creative commons yang digunakan.
ARTERI : Jurnal Ilmu Kesehatan is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.